A5016786663- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- Radiomics and Machine Learning in Medical Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Immune cells in cancer
- Gastric Cancer Management and Outcomes
- Cancer Research and Treatments
- Cancer Diagnosis and Treatment
- Vitamin K Research Studies
- Peptidase Inhibition and Analysis
- RNA modifications and cancer
- Metastasis and carcinoma case studies
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Hypoxia, and Metabolism
- Pancreatitis Pathology and Treatment
- AI in cancer detection
- Kruppel-like factors research
- Bone and Dental Protein Studies
- Cancer-related molecular mechanisms research
- Pleural and Pulmonary Diseases
Tianjin Medical University Cancer Institute and Hospital
2012-2024
Zhejiang University
2022-2024
Huazhong University of Science and Technology
2001-2023
National Clinical Research
2023
Wuhan Puai Hospital
2009-2023
Tianjin Medical University
2007-2020
Handok (South Korea)
2020
National Clinical Research Center for Digestive Diseases
2016-2020
The First People's Hospital of Tianmen
2008
Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative regimens may combine benefits of both to long-term outcomes. Download a PDF the Research Summary. We randomly assigned NSCLC (stage II IIIB [N2 node stage] according eighth edition AJCC Cancer Staging Manual) receive platinum-based chemotherapy plus durvalumab placebo administered intravenously every 3 weeks for 4 cycles before surgery, followed by 12...
Abstract Background: Recent trials have demonstrated the clinical benefit of immunotherapy in either neoadjuvant or adjuvant resectable (R) NSCLC setting. AEGEAN (NCT03800134) is a randomized, double-blind, placebo (PBO)-controlled trial assessing durvalumab (D) + chemotherapy (CT) followed by surgery (Sx) and D patients (pts) with R-NSCLC. Methods: Adults treatment (Tx)-naïve R-NSCLC (stage II-IIIB[N2]; AJCC 8th ed) ECOG PS 0/1 were randomized (1:1) to receive 1500 mg PBO IV platinum-based...
Abstract The combination of immune checkpoint inhibitors (ICIs) with chemotherapy (chemoimmunotherapy) in the neoadjuvant setting have achieved favorable clinical benefits non-small cell lung cancer (NSCLC), but mechanism responses remain unclear. We provide a rich resource 186,477 individual cells from 48 samples four treatment-naive and eight chemoimmunotherapy treated IIIA NSCLC patients (responders versus non-responders) by single-cell RNA-seq TCR-seq. observed synergistic increase B CD4...
Despite significant benefits from targeted therapy in patients with driver mutations, inevitable drug resistance usually occurred non-small cell lung cancer, highlighting the necessity for sequential treatments to prolong overall survival. Unfortunately, durable response has not been reported posterior-line of cases acquired
N-acetylcysteine has been widely used as a nutritional supplement and drug in humans for its antioxidant properties. The complement activation fragment C5a is strong proinflammatory molecule that mediates cell adhesion, chemotaxis, the complex biological functions. However, effect of NAC on C5a, relationship those two with cisplatin-induced acute kidney injury are unknown. In cisplatin induced AKI mouse model, mice administration had marked improvement renal function (BUN Cr), decreased...
A small proportion of patients with non-small cell lung cancer (NSCLC) experience objective clinical benefit after neoadjuvant programmed death 1 (PD-1) blockade. therapeutic regimen combining immune checkpoint blockade chemotherapy might improve the treatment effect, but such a has not been tested in resectable stage IIIA/IIIB NSCLC.A retrospective study 35 IIIA and IIIB NSCLC who were treated chemoimmunotherapy (NCIO) was performed. Patients evaluated for pathological complete response...
The SARI (suppressor of AP-1, regulated by IFN) gene, which is also called BATF2, associated with the risk several kinds cancer, and loss expression frequently detected in aggressive metastatic cancer. However, functional role lung adenocarcinoma remains unknown. We have shown that initiates epithelial-mesenchymal transition (EMT), visualized repression E-cadherin up-regulation vimentin cell lines clinical specimens. Using a human xenograft-mouse model, we observed knocking down endogenous...
The combination of PD-1 blockade with neoadjuvant chemotherapy (NAC) has achieved unprecedented clinical success in non-small cell lung cancer (NSCLC) compared to NAC alone, but the underlying mechanisms by which augments effects remain incompletely elucidated. Single-cell RNA sequencing was performed on CD45+ immune cells isolated from surgically resected fresh tumors seven NSCLC patients receiving or pembrolizumab and (NAPC). Multiplex fluorescent immunohistochemistry FFPE tissues before...
Background Osteopontin (OPN) was identified as one of the leading genes that promote metastasis malignant tumor. However, mechanism by which OPN mediates in non-small cell lung cancer (NSCLC) remains unknown. The aim study is to investigate biological significance and related molecular expression line. Methods Lentiviral-mediated RNA interference applied inhibit metastatic human NSCLC line (A549). invasion, proliferation, were evaluated OPN-silenced A549 cells vitro vivo . further...
8004 Background: The efficacy, safety and ideal treatment duration of adjuvant icotinib (first-generation EGFR tyrosine kinase inhibitor) for patients with completely resected EGFR-mutated non-small-cell lung cancer (NSCLC) after chemotherapy were not known in 2014, when this study was initiated. This phase 3 trial investigated whether following improves clinical outcomes compared observation stage II-IIIA NSCLC harboring mutation. Methods: is a multicenter, randomized, open-label, trial....
Abstract Adoptive cell therapy (ACT) was one of the most promising anti-tumor modalities that has been confirmed to be especially effective in treating hematological malignancies. However, clinical efficacy ACT on solid tumor greatly hindered by insufficient tumor-infiltration cytotoxic CD8 + T cells. Herein, we constructed a nanoplatform termed dual-binding magnetic nanoparticles (DBMN) comprised PEG-maleimide (Mal), hyaluronic acid (HA) and Fe 3 O 4 for adoptive cell-modification...
// Xiaoliang Zhao 1, 2, 3, 4 , Yanjun Su Jian You Liqun Gong Zhenfa Zhang Meng Wang Zhenqing Zhen Xiaolin Li Changli 1 Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, 300060, P.R. China 2 Center, P.R 3 Key Laboratory Prevention Therapy, National Clinical Research Center for Correspondence to: Wang, email: wangchangli@medmail.com.cn Keywords: recombinant human endostatin, neoadjuvant chemotherapy, non-small cell lung cancer Received: March 10, 2016...
: Immunotherapy is one of the most effective treatments for patients with advanced lung cancer. In many non-small cell cancer (NSCLC) cases, tumor centrally located. For such patients, sleeve lobectomy has been considered as a more therapeutic option compared pneumonectomy, achieving better long-term survival and quality life no increase in morbidity or mortality. Until now, there have studies regarding efficacy safety neo-adjuvant chemo-immunotherapy prior to From January 2019 through...
To compare survival of patients with non-small cell lung cancer (NSCLC) who underwent surgical resection and lymph node sampling based on guidelines proposed by the American College Surgeons Oncology Group (ACOSOG), National Comprehensive Cancer Network (NCCN), OSI Pharmaceutical RADIANT trial, International Association for Study Lung (IASLC). Medical records NSCLC from 2001 to 2008 at our hospital were reviewed. Staging was according 7th edition AJCC TNM classification cancer. Patients...
Abstract Background Immunotherapy has been proved to have a large effect on extensive‐stage small cell lung cancer, but the role of immunotherapy in limited‐stage small‐cell cancer (LS‐SCLC) is still unknown. Methods A retrospective study six patients with LS‐SCLC who were treated neoadjuvant chemoimmunotherapy (durvalumab plus etoposide combined cisplatin) was performed. Patients evaluated by safety, feasibility and pathologic responses chemoimmunotherapy. Results Neoadjuvant durvalumab...
Mortality from lung cancer has ranked high among cancers for many years. Early detection of is critical disease prevention, cure, and mortality rate reduction. Many existing methods on nodules can achieve sensitivity but meanwhile introduce an excessive number false-positive proposals, which clinically unpractical. In this paper, we propose the multi-head spatial attention network, shortly MHSnet, to address crucial issue. Specifically, first detectors skip connections capture multi-scale...